Role for HCV antigen detection: a new generation of assays

Slides:



Advertisements
Similar presentations
Designing Clinical Research Studies An overview S.F. O’Brien.
Advertisements

CORRELATION BETWEEN HBSAG LEVEL AND VIRAL LOAD
High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.
HIV Testing CDC power point edited by M. Myers
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
Three Traps to Avoid & Bioinformatics Advantage 1.) In the Discovery Phase Its ok to “Fish” for significant relationships in your data (i.e. look at.
The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis.
Hepatitis C Molecular Diagnosis in the Era of DAAs July 22, 2016, Tehran Ali Namvar Ph.D of Molecular Genetics Iranian Comprehensive Hemophilia Care Center.
Introduction to Quality Assurance. Quality assurance vs. Quality control.
Cepheid Symposium IAS 2017 Gwynn Stevens, PhD Director of Virology
Hepatitis C.
Abbott HCV core Ag and HCV RNA Comparison Study
Emory University School of Medicine Department of Medicine
Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10.
Experience in Testing of Genotypes of B19
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Diagnostics in hepatitis C: The end of response-guided therapy?
In The Name of God.
Ann Intern Med. 2017;167(1):1-7. doi: /M Figure Legend:
*Dr. Mushtak T. S Al-Ouqaili **Dr. Yasin Hamad Majeed
Hepatitis C Virus RNA Real-Time Quantitative RT-PCR Method Based on a New Primer Design Strategy  Lida Chen, Wenli Li, Kuo Zhang, Rui Zhang, Tian Lu,
Viral Load (copies/ml)
Phase 3b Treatment-Naive
HCV & liver transplantation
Diagnosis and Point of Care Testing of Hepatitis C
California Clinical Laboratory Association
WHY GENETIC COUNSELING IS IMPORTANT
FACILITATOR VERSION Case Four: I just have antibodies to this
Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10.
Hepatitis C Virus RNA Real-Time Quantitative RT-PCR Method Based on a New Primer Design Strategy  Lida Chen, Wenli Li, Kuo Zhang, Rui Zhang, Tian Lu,
Acute HIV Infection and PrEP: Opportunities and challenges
The importance of randomisation in evaluation of treatments for Acute Myeloid Leukaemia Lessons from the UK NCRI AML16 and LI-1 trials Ian Thomas, Senior.
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Jeffrey J. Germer, BS, Nizar N. Zein, MD  Mayo Clinic Proceedings 
Performance Characteristics of a Quantitative Hepatitis C Virus RNA Assay Using COBAS AmpliPrep Total Nucleic Acid Isolation and COBAS TaqMan Hepatitis.
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
Hepatitis Primary Care: Clinics in Office Practice
INTEGRATING HIV AND HCV TESTING.
Boceprevir in Treatment Naive SPRINT-2
PROPPR Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. 
Case Four: I just have antibodies to this
Volume 42, Issue 1, Pages (January 2005)
Treatment with the second-generation HCV protease inhibitor BI results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1.
Volume 140, Issue 2, Pages e1 (February 2011)
Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 Infection  Charles D. Howell, Thomas.
Diagnostics in hepatitis C: The end of response-guided therapy?
Virological tools to diagnose and monitor hepatitis C virus infection
Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K
Volume 128, Issue 2, Pages (February 2005)
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients
Volume 141, Issue 5, Pages (November 2011)
Managing Age-Related Clinical Issues in Hemophilia
Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis.
Christoph Sarrazin, Stefan Zeuzem  Gastroenterology 
Volume 142, Issue 6, Pages (May 2012)
Volume 5, Issue 1, Pages e35-e44 (January 2018)
M. Korva, A. Saksida, N. Kejzar, C. Schmaljohn, T. Avŝiĉ-Zupanc 
Chronic Hepatitis C Therapy: Changing the Rules of Duration
SoGAT meeting XXI May (2009), Brussels, Belgium
FACILITATOR VERSION Case Four: I just have antibodies to this
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Challenges for Blood Donor Confirmatory Testing Algorithms
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
Pei-Yuan Su,Yu-Chun Hsu,Shun-Sheng Wu,Wei-Wen Su,Maw-Soan Soon
Association of HIV-1 replication fitness, as measured in a whole-virus parallel infection assay, with ability to control viremia after treatment interruption.
Presentation transcript:

Role for HCV antigen detection: a new generation of assays Blood Borne Virus Unit Virus Reference Department Centre for Infections HPA Colindale 13 May 2019

Samples used for the study Part 1: 94 acute phase seronegative plasma donors, 51 of which contained detectable RNA genotyped, titrated as appropriate Part 2: Plasma samples from 65 individuals in a randomised clinical trial of Ribavarin/IFN samples from first 14 days of treatment to assess early dynamics

Part 1 inferences to be drawn:- Proficient across limited selection of genotypes 1-3 available Linearity also maintained over 3 log10 Interpolated LOD in range 2-3 log10

Part 2: 300 samples from 65 patients HCV Ag log10 f/mole HCV RNA Viral load log10 iu/ml

Part 2: Pre- or D3 samples from 59 patients

49 RA 4.00 7.00 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 Base D3 D7 D10 D14 W12 Time log HCV Ag 5.00 6.00 7.00 log HCV RNA 3.50 6.00 3.00 5.00 2.50 4.00 2.00 log HCV RNA log HCV Ag 3.00 1.50 2.00 1.00 0.50 1.00 0.00 0.00 Base D3 D7 D10 D14 W12 Time 64 Time 0.00 0.50 1.00 1.50 2.00 2.50 3.00 BASE D7 D14 W12 log HCV Ag 4.00 5.00 6.00 log HCV RNA

257 292 0.5 1 1.5 2 2.5 3 3.5 4 Base D3 D7 D10 D14 W12 Time log HCV Ag 5 6 7 log HCV RNA 4 6 3.5 5 3 4 2.5 log HCV Ag 2 3 log HCV RNA 1.5 2 1 1 0.5 Base D3 D7 D14 W12 Time 268 4.5 8 4 7 3.5 6 3 5 2.5 log HCV RNA 4 log HCV Ag 2 3 1.5 1 2 0.5 1 Base D3 D7 D14 W12 Time

Part 2 inferences to be drawn:- Good correlation between HCV Ag quantitification and HCV RNA BUT NOT absolute, what is nature of the relationship? Response to R/IFN paralleled by both markers Idiosyncrasies rare but significant, reason? Qualitative therapy prediction possible early Need to pin antigenaemia against HCV RNA for each patient Positioning- adjunct or alternative? High risk population or resource-limited sites?

Thanks to: Prof Howard Thomas and colleagues for permission to use the “Mild Trial” samples Paul Grant, UCL for HCV RNA data Nigel Wallis, Phil Tuke, Siew Lin Ngui and colleagues in BBVU, VRD Abbott Diagnostics for Architect reagents and support